Ivantis gets $27M boost for trials of microstent in eye patients

02/4/2013 | Healio

A round of Series B financing led by Ascension Health Ventures has brought in $27 million for Ivantis. The company will use the money to conduct four global clinical studies of its Hydrus microstent, a tiny device that assists in restoring a glaucoma patient's natural eye outflow pathway.

View Full Article in:

Healio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR